Shares of Editas Medicine, Inc. (EDIT, Financial), a biopharmaceutical company, experienced a notable drop of 5.18%. The stock is currently priced at $3.21 per share, with a trading volume of 976,255 shares and a turnover rate of 1.18%. The price fluctuation stands at 6.36%.
According to recent financial reports, Editas Medicine generated $513,000 in revenue but reported a net loss of $67.61 million. The earnings per share stood at -$0.82, and the gross profit was -$907,000, resulting in a price-to-earnings ratio of -1.38.
Regarding analyst ratings, 53% of 19 participating institutions have recommended a buy, while 47% suggest holding the stock. No analysts recommended selling the stock.
In the broader biotechnology sector, the overall decline was 0.09%. Within the sector, Scholar Rock Holding Corporation, Nls Pharmaceutics Ltd, and Oncolytics Biotech Inc. posted significant gains, while Aditxt, Inc., Tc Biopharm (Holdings) Plc, and Phio Pharmaceuticals Corp. showed high activity with turnover rates of 1645.65%, 86.53%, and 60.56%, respectively. Notable price fluctuations were seen in Scholar Rock Holding Corporation, Reviva Pharmaceuticals Holdings Inc, and Akari Therapeutics Plc, with amplitudes of 107.82%, 39.46%, and 37.93% respectively.
Editas Medicine is a clinical-stage genome editing company focusing on developing transformative genome medicines for serious diseases. The company uses a proprietary platform based on CRISPR/Cas9 technology, which involves a protein-RNA complex designed to identify and repair DNA sequences.
